Jean‐François Chatal

Author

Also Known As

Chatal, Jean-François, J F Chatal, JEAN-FRANCOIS CHATAL, JEAN-FRANÇOIS CHATAL, Jean-Francois Chatal, Jean-François Chatal, Jean-François Chatal, Jean‐François Chatal

103

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Inserm Nantes Université Institut Génétique Nantes Atlantique Center for Molecular Medicine and Immunology Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers

About

Jean‐François Chatal is an author at Inserm specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	797
2	Engineering	8	8	295
3	Health Sciences	3	3	111
4	Natural Sciences	2	2	32
5	Biochemistry	1	1	17

Jean‐François Chatal

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma Jacques Barbet, L. Campion, Françoise Kraeber‐Bodéré, The Journal of Clinical Endocrinology & Metabolism	2005	399
Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group Jean‐François Chatal, L. Campion, Françoise Kraeber‐Bodéré, Journal of Clinical Oncology	2006	228
Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement Françoise Kraeber‐Bodéré, L. Campion, Caroline Rousseau, European Journal of Nuclear Medicine and Molecular Imaging Surgical OncologyRadiation MedicineUrologyGenitourinary CancerBone Involvement	2000	134
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Chien‐Hsing Chang, Robert M. Sharkey, Edmund A. Rossi, PubMed EngineeringTargeted DeliveryImmunologyAntibody LocalizationImmunotherapy	2002	129
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. Françoise Kraeber‐Bodéré, Caroline Rousseau, Caroline Bodet‐Milin, PubMed	2006	127
High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma Franck Morschhauser, Françoise Kraeber‐Bodéré, William A. Wegener, Journal of Clinical Oncology	2010	114
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine Férid Haddad, Ludovic Ferrer, Arnaud Guertin, European Journal of Nuclear Medicine and Molecular Imaging Radiation OncologyProton TherapyNuclear Medicine	2008	113
Cancer imaging and therapy with bispecific antibody pretargeting David M. Goldenberg, Jean‐François Chatal, Jacques Barbet, Update on Cancer Therapeutics Oncologic ImagingMedicineTherapeutic ImagingAntibody EngineeringOncology	2007	94
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? Robert M. Sharkey, A. J. Brenner, J. D. Burton, PubMed	2003	92
Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy A. Oudoux, Pierre‐Yves Salaün, Claire Bournaud, The Journal of Clinical Endocrinology & Metabolism	2007	91

Page 1